Regenxbio (RGNX) EBITDA (2014 - 2025)

Regenxbio's EBITDA history runs 12 years deep, the most recent figure standing at -$57.6 million for Q4 2025.

• On a quarterly basis, EBITDA fell 12.2% year-over-year to -$57.6 million in Q4 2025; TTM through Dec 2025 was -$161.2 million, a 30.92% increase from a year earlier, with the FY2025 full-year figure at -$161.2 million, up 30.92% from the prior year.
• EBITDA fell to -$57.6 million in Q4 2025 per RGNX's latest filing, from -$52.4 million in the prior quarter.
• Across five years, EBITDA topped out at $313.6 million in Q4 2021 and bottomed at -$73.1 million in Q2 2023.
• The 5-year median for EBITDA is -$59.9 million (2022), against an average of -$38.3 million.
• Biggest YoY gain for EBITDA was 684.51% in 2021; the steepest drop was 511.07% in 2021.
• Year by year, EBITDA stood at $313.6 million in 2021, then tumbled by 118.42% to -$57.8 million in 2022, then decreased by 10.61% to -$63.9 million in 2023, then climbed by 19.62% to -$51.4 million in 2024, then retreated by 12.2% to -$57.6 million in 2025.
• Per Business Quant, the three latest RGNX EBITDA figures stand at -$57.6 million (Q4 2025), -$52.4 million (Q3 2025), and -$63.3 million (Q2 2025).